OZANIMOD HYDROCHLORIDE | BRISTOL | ||
EQ 0.23MG BASE,EQ 0.46MG BASE,EQ 0.92MG BASE | |||
Yes | No | ||
2038-Sep-30 | 2025-Mar-25 | ||
None | None | ||
None | No | ||
ZEPOSIA is a sphingosine 1-phosphate receptor modulator indicated for the treatment of: • Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. • Moderately to severely active ulcerative colitis (UC) in adults. |
0 | 0 | 0 |
Total Other Developers | 2 |
---|
Drugs with Suitability | No |
---|
EQ 0.23MG BASE | ** | ** | - | - | - |
EQ 0.46MG BASE | ** | ** | - | - | - |
EQ 0.92MG BASE | ** | ** | - | - | - |
NDA Sales Available | Total Generic Sales Available |
---|---|
Yes | 0 |
ANDA No | Generic Co | Manufacturer Name | Operations | Manufacturer Address | Country |
---|
Download GenUS Drug Report
Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023
+91 94997 68112
nimish@researchdelta.com